+86 1234567890
@huapeptide.cn
DSIP (delta sleep inducing peptide or delta sleep peptide) was first discovered in 1974 by the Swiss G. Schoeneberger and M. Monnier, who isolated it from the brain blood of sleeping rabbits. Since the discovery, several hundred articles have been published, most of which describe the localization and involvement of the peptide in the brain and peripheral nervous system.
The main property of DSIP is the ability to induce a stage of non-REM sleep, which is effective in combating insomnia. The peptide was found to affect electrophysiological activity, neurotransmitter levels in the brain, circadian and locomotor structures, hormonal levels, psychological performance and concentration, and the activity of neuropharmacological drugs.
A pronounced effect on withdrawal symptoms, including pain conditions in alcoholics and drug addicts, was noted. It has also been shown to be effective in chronic pain, including migraines.
Basic Info. LL37 is an antimicrobial peptide with 37 residues, belonging to the humanized cathelicidin family. It has a wide range of antimicrobial activities. such as inhibitory effects on bacterial, fungal, and viral pathogens It is also an immune modulator that participates in the regulation of the immune system ...
Basic Info. Cagrilintide, a long-acting analogue of the hormone amylin, presents a promising new approach to tackling obesity. Unlike many weight-loss drugs that only target one mechanism, cagrilintide works on multiple fronts. It suppresses appetite by promoting feelings of fullness (satiety) and slows down gastric emptying, making people feel full for longer periods of time. Early trials of cagrilintide have shown that it leads to significant weight loss compared to placebo and even other peptides like liraglutide, which is currently used for obesity treatment. In one study, participants taking cagrilintide lost up to 10.8% of their body weight over 26 weeks, outperforming those on liraglutide. Sustained weight loss like this can help break the cycle of yo-yo dieting. ...
Basic Info. ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes. ARA 290 has been shown to be effective in the reduction of inflammation and activation of the healing process in a wide variety of preclinical models as well as in patients. With respect to diabetes, substantial recent work has shown that rhEPO can improve the diabetic state in animal models . However, in addition to interacting with the innate repair receptor in a paracrine/autocrine manner, EPO also functions as a circulating hormone via its interaction with the EPO receptor homodimer that mediates hematopoiesis. ...
Basic Info. Cerebrolysin, a neuropeptide preparation, has been extensively studied in rat models to evaluate its potential in treating neurological impairments. Research indicates that Cerebrolysin can significantly enhance cognitive functions and promote neuroprotection following brain injuries. It is rats subjected to mild traumatic brain injury (mTBI) were treated with Cerebrolysin. The results demonstrated notable improvements in long-term spatial learning and memory, as assessed by the Morris water maze test. Additionally, treated rats exhibited reduced accumulation of amyloid precursor protein and decreased astrogliosis, suggesting neuroprotective effects. ...
Basic Info. EPO injection (Erythropoietin Injection) is a medicine that helps your bone marrow to produce more red blood cells.It is used to treat a type of anemia caused by kidney disease. It is also used to treat anemia caused by cancer chemotherapy and by taking medicines to treat HIV. ...
